Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sovateltide - Midwestern University/Pharmazz

Drug Profile

Sovateltide - Midwestern University/Pharmazz

Alternative Names: IRL-1620; PMZ-1620; SPI-1620

Latest Information Update: 03 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Illinois at Chicago
  • Developer Pharmazz; Spectrum Pharmaceuticals
  • Class Antidementias; Antineoplastics; Imaging agents; Neuroprotectants; Peptides; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Angiogenesis modulating agents; Diagnostic imaging enhancers; Endothelin B receptor agonists; Neurogenesis stimulants; Neuron modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Solid tumours; Stroke
  • Phase II Alzheimer's disease; Spinal cord injuries
  • Preclinical Cerebrovascular disorders; Neurodegenerative disorders
  • Discontinued Biliary cancer; Non-small cell lung cancer

Most Recent Events

  • 29 Oct 2019 Pharmazz has patent protection for endothelin-B receptor agonist in Australia
  • 30 Sep 2019 Phase-III clinical trials in Stroke in India (IV) (NCT04047563)
  • 30 Sep 2019 Pharmazz completes a phase II trial in Stroke in India (IV) (NCT04046484)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top